ライフサイエンスコーパス: nucleic acid amplification

1 ng aptamer labels, hybridization assays, and nucleic acid amplification.

2 tion of single-cell genomic DNA using linear nucleic acid amplification.

3 reagent storage, sample transportation, and nucleic acid amplification.

4 sufficiently pure to support high-efficiency nucleic acid amplification.

5 ccurate thermal control and the detection of nucleic acid amplification.

6 pe biosensor compared favorably to those for nucleic acid amplification.

7 the bench-top optical systems in monitoring nucleic acid amplification.

8 miR-19b and miR-20a is realized without any nucleic acid amplification.

9 rent gold standard fluorescence detection of nucleic acid amplification.

10 Without nucleic acid amplification, a detection limit of 1 pM is

11 to its ability to perform rapid and specific nucleic acid amplification and analysis on small volumes

12 dimensionality and sensitive detection using nucleic acid amplification and analysis techniques.

13 echnologies for milk analysis, in particular nucleic acid amplification and biosensors, is reviewed h

14 Integrating sample preparation with nucleic acid amplification and detection in a cost-effec

15 Nucleic acid amplification and detection plays an increa

16 y describe recent developments in isothermal nucleic acid amplification and detection, and focus on e

17 The assay involved multiplex nucleic acid amplification and microarray hybridization

18 x priming amplification, to greatly simplify nucleic acid amplification and real-time quantification

19 other biological assays, such as isothermal nucleic acid amplification and restriction enzyme digest

20 Direct molecular assay (ST Direct) relies on nucleic acid amplification and solid array-based amplico

21 or microbial nucleic acid enrichment, random nucleic acid amplification, and automated sequence simil

22 Gram-Positive (BCID-GP) Panel is a multiplex nucleic acid amplification assay based on competitive DN

23 icroscopy with the GeneXpert MTB/RIF (Xpert) nucleic acid amplification assay could reduce testing ti

24 utomated assay provides a useful alternative nucleic acid amplification assay for clinical laboratori

25 latform in which a simple, dry-reagent-based nucleic acid amplification assay is combined with a port

26 e potential of combining a dry-reagent-based nucleic acid amplification assay with an electrochemical

27 Nucleic acid amplification assays had limited abilities

28 assay to results from two currently approved nucleic acid amplification assays in 1,722 female and 1,

29 Isothermal nucleic acid amplification assays such as the loop media

30 croBAR is capable of carrying out isothermal nucleic acid amplification assays with real-time fluores

31 edure has not transformed the application of nucleic acid amplification assays.

32 o the species level by phenotypic systems or nucleic acid amplification assays.

33 ey components necessary to expand the use of nucleic acid amplification-based detection assays toward

34 mic range for the new Xpert MTB/RIF assay, a nucleic acid amplification-based diagnostic system that

35 Molecular typing is an important adjunct to nucleic acid amplification-based diagnostics.

36 Alere i Influenza A&B is an isothermal nucleic acid amplification-based integrated system for d

37 rains from direct clinical samples used with nucleic acid amplification-based tests.

38 h not only overcomes many inherent issues of nucleic acid amplification but also provides unprecedent

39 assembly (CHA) is one of the most promising nucleic acid amplification circuits based on toehold-med

40 ction methods, including cell-based methods, nucleic acid amplification detection methods, and biosen

41 oxide-semiconductor microchip technology for nucleic acid amplification detection; and (iii) a smartp

42 pped with a sample pretreatment device and a nucleic acid amplification device for the rapid diagnosi

43 ave been made in the development of portable nucleic acid amplification devices for near-patient use.

44 ction of viral RNA in both tests is based on nucleic acid amplification followed by hybridization to

45 development for arsenic detection, including nucleic acid amplification for signal enhancement and de

46 Nucleic acid amplification for the detection of severe a

47 e multicenter clinical validation study of a nucleic acid amplification in vitro diagnostic test for

48 Nucleic acid amplification includes both polymerase chai

49 Nucleic acid amplification is an essential process in bi

50 uorescence signal enhancement via isothermal nucleic acid amplification is an important approach for

51 Isothermal nucleic acid amplification is becoming increasingly impo

52 Real-time, isothermal, digital nucleic acid amplification is emerging as an attractive

53 Combining loop-mediated isothermal nucleic acid amplification (LAMP) and bioluminescent ass

54 integrated with real-time DNA/RNA isothermal nucleic acid amplification: Loop-mediated isothermal amp

55 ion (C2CA) is a specific and precise cascade nucleic acid amplification method consisting of more tha

56 ation (LAMP) of DNA is a powerful isothermal nucleic acid amplification method that can generate upwa

57 Loop-mediated amplification (LAMP) is a nucleic acid amplification method that has been widely u

58 est, Staph ID/R, combines a rapid isothermal nucleic acid amplification method, helicase-dependent am

59 olymerase amplification (RPA), an isothermal nucleic acid amplification method, is enhancing our abil

60 (CDC) recommends the performance of a direct nucleic acid amplification method, regardless of smear r

61 We recently reported a novel isothermal nucleic acid amplification method, Strand Invasion-Based

62 Using the DNase-sequence-independent viral nucleic acid amplification method, we identified several

63 Real-time nucleic acid amplification methods can be extremely usef

64 aboratory diagnosis, rapid antigen tests and nucleic acid amplification methods may also play a usefu

65 Isothermal nucleic acid amplification methods offer significant adv

66 Nucleic acid amplification methods such as the PCR have

67 Current nucleic acid amplification methods to detect Mycobacteri

68 and other NGU pathogens were detected using nucleic acid amplification methods, and DNA sequencing w

69 For nucleic acid amplification methods, controlled DNA denat

70 hese limitations, with a focus on isothermal nucleic acid amplification methods.

71 llent performance of rapid tuberculosis (TB) nucleic acid amplification (NAA) tests and the clear ben

72 Recently, nucleic acid amplification (NAA) tests have shown promis

73 t system (BD Affirm VPIII) was compared with nucleic acid amplification (NAA)-based assays for determ

74 Nucleic acid amplification of biomarkers is increasingly

75 Specimens were analyzed by employing nucleic acid amplification panels.

76 th the current availability of point-of-care nucleic acid amplification platforms (eg, Xpert Edge), t

77 Currently available nucleic acid amplification platforms for tuberculosis (T

78 c devices of the most popular technology for nucleic acids amplifications, polymerase chain reaction

79 ntial, numerous technical issues, especially nucleic acid amplification, probe specificity, and inter

80 n developed from an understanding of natural nucleic acid amplification processes.

81 ircuitry can be used to transduce isothermal nucleic acid amplification products into signals that ca

82 idic systems for the compartmentalization of nucleic acid amplification reactions.

83 g and transducing signals at the terminus of nucleic acid amplification reactions.

84 on-specific amplification in EXPAR and other nucleic acid amplification reactions.

85 field effect transistor methods for sensing nucleic acid amplification rely on establishing the flui

86 nical laboratory include biological culture, nucleic acid amplification, ribosomal protein characteri

87 ing was observed, the failure was due to the nucleic acid amplification step rather than limitations

88 Conversely, diagnostic methods based on nucleic acid amplification stepped forwards owing to the

89 C. difficile assay is an integrated, closed, nucleic acid amplification system that automates sample

90 ert Flu Assay cartridge is a next-generation nucleic acid amplification system that provides multiple

91 sothermal amplification (LAMP) is a powerful nucleic acid amplification technique due to its rapid an

92 ation of DNA (LAMP) is a powerful isothermal nucleic acid amplification technique that can accumulate

93 omewhat limited applications of this classic nucleic acid amplification technique.

94 Performing nucleic acid amplification techniques (NAATs) in digital

95 Nucleic acid amplification techniques (polymerase chain

96 ion of these methods that are independent of nucleic acid amplification techniques and could largely

97 e for nucleic acids that can be analyzed via nucleic acid amplification techniques has several advant

98 Nucleic acid amplification techniques have been among th

99 Several nucleic acid amplification techniques have been develope

100 tion (WHO) international standards (ISs) for nucleic acid amplification techniques were established t

101 broad range of assays, including isothermal nucleic acid amplification techniques, enzyme-based immu

102 cluding both antigen detection and multiplex nucleic acid amplification techniques, is becoming more

103 re hospitals were tested for influenza using nucleic acid amplification techniques.

104 dramatically shorten the time-to-results of nucleic acid amplification techniques.

105 Rapid isothermal nucleic acid amplification technologies can enable diagn

106 New sample-in, answer-out nucleic acid amplification technologies for point-of-car

107 the maternal GBS colonization status, rapid nucleic acid amplification technologies have been develo

108 o known as hyperbranched RCA) are isothermal nucleic acid amplification technologies that have gained

109 study period, which was analyzed relative to nucleic acid amplification technology (NAT) yield to est

110 Subsequently, progressive implementation of nucleic acid-amplification technology (NAT) screening fo

111 ratory viral panel (eSensor RVP) multiplexed nucleic acid amplification test (GenMark Diagnostics, In

112 FilmArray Respiratory Panel (RP) multiplexed nucleic acid amplification test (Idaho Technology, Inc.,

113 This work presents an on-chip isothermal nucleic acid amplification test (iNAAT) for the multiple

114 sitive for stx by an alternative FDA-cleared nucleic acid amplification test (NAAT) but were negative

115 Evaluating the clinical performance of a new nucleic acid amplification test (NAAT) for Mycoplasma ge

116 , with a validated reverse transcription-PCR nucleic acid amplification test (NAAT) for SARS-CoV-2 RN

117 The Abbott RealTime MTB assay is a nucleic acid amplification test (NAAT) for the detection

118 the performance of a new in vitro diagnostic nucleic acid amplification test (NAAT) for the detection

119 To investigate the performance of a nucleic acid amplification test (NAAT) for the diagnosis

120 atis or N. gonorrhoeae, two or more positive nucleic acid amplification test (NAAT) results, or a sin

121 seria gonorrhoeae (gonococcus [GC])-positive nucleic acid amplification test (NAAT) results: (i) repe

122 ollection) and a positive stool C. difficile nucleic acid amplification test (NAAT) were enrolled.

123 Culture and a nucleic acid amplification test (NAAT) were used to dete

124 inically significant diarrhea and a positive nucleic acid amplification test (NAAT), per US guideline

125 s and symptoms, in contrast with only 3 of 8 nucleic acid amplification test (NAAT)-based studies (P

126 sistant tuberculosis (MDR-TB) screening, all nucleic acid amplification test (NAAT)-positive respirat

127 ents with suspected CDI were tested with the nucleic acid amplification test (NAAT; BD MAX Cdiff assa

128 ave developed an economical, high-throughput nucleic acid amplification test (NAT) for blood-borne vi

129 tially infected sites, defined as a negative nucleic acid amplification test 2 weeks post treatment.

130 sts (wet mount, culture, a rapid test, and a nucleic acid amplification test [NAAT]) were performed o

131 ,749 vulvovaginal-swab specimens with both a nucleic acid amplification test and a polymer conjugate-

132 true-negative or false-negative relative to nucleic acid amplification test and/or enzyme immunoassa

133 point was microbiological cure by a negative nucleic acid amplification test at 4 weeks.

134 The Alere i strep A test is an isothermal nucleic acid amplification test designed to offer highly

135 12 months with STI testing (rectal and urine nucleic acid amplification test for gonorrhea and chlamy

136 ary tuberculosis, as confirmed by a positive nucleic acid amplification test for Mycobacterium tuberc

137 at first vaginal intercourse and a positive nucleic acid amplification test for sexually transmitted

138 ple, sample-to-answer, on-demand, multiplex, nucleic acid amplification test for syndromic diagnosis

139 Qiagen artus C. difficile QS-RGQ kit, a new nucleic acid amplification test for the detection of Clo

140 opment of an internally controlled multiplex nucleic acid amplification test for the detection of den

141 pert MTB/RIF, the most widely used automated nucleic acid amplification test for tuberculosis, is ava

142 Newer rapid nucleic acid amplification test platforms, including poi

143 In addition, positive nucleic acid amplification test results should be confir

144 s of a new, high-throughput, fully automated nucleic acid amplification test system for the detection

145 ased sensor system for a point-of-care (POC) nucleic acid amplification test that can quantitatively

146 ollection) and a positive stool C. difficile nucleic acid amplification test were enrolled.

147 The Xpert MTB/RIF (Xpert) assay is a rapid nucleic acid amplification test widely used in settings

148 only confirmed CDAD (by toxin immunoassay or nucleic acid amplification test) as failure.

149 , we enrolled men who have sex with men with nucleic acid amplification test-diagnosed pharyngeal gon

150 COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than

151 t results were resolved using an alternative nucleic acid amplification test.

152 t MTB/RIF (Xpert), a novel, semiautomated TB nucleic-acid amplification test, has renewed interest in

153 Digital nucleic acid amplification testing (dNAAT) and analysis

154 of 3 algorithms that detect AHI based on HIV nucleic acid amplification testing (EarlyTest algorithm)

155 Here we report the development of a mobile nucleic acid amplification testing (mobiNAAT) platform u

156 utility of Mycobacterium tuberculosis direct nucleic acid amplification testing (MTD) for pulmonary t

157 rator for improving the harmonization of BKV nucleic acid amplification testing (NAAT) and enabling c

158 clinically significant diarrhea and positive nucleic acid amplification testing (NAAT) and received C

159 We evaluated criteria to reduce unnecessary nucleic acid amplification testing (NAAT) for viral path

160 Nucleic acid amplification testing (NAAT) has become the

161 Nucleic acid amplification testing (NAAT) is increasingl

162 Nucleic acid amplification testing (NAAT) is the preferr

163 virus infection (AHI); however, the cost of nucleic acid amplification testing (NAAT) makes individu

164 d who had 2 consecutive negative results per nucleic acid amplification testing (NAAT) of viral sampl

165 onreactive samples were pooled and tested by nucleic acid amplification testing (NAAT) to identify ac

166 Cervical culture and nucleic acid amplification testing (NAAT) were completed

167 However, nucleic acid amplification testing (NAAT) with the Xpert

168 chomatis infection in certain populations by nucleic acid amplification testing (NAAT), as they invol

169 94.7%, respectively, after 48 h compared to nucleic acid amplification testing (NAAT).

170 human immunodeficiency virus type 1 (HIV-1) nucleic acid amplification testing (NAAT).

171 This study presents the verification of nucleic acid amplification testing (NAAT; Gen-Probe Apti

172 ccepted for transplantation.Universal use of nucleic acid amplification testing (NAT) for the screeni

173 igenic organisms (toxigenic culture [TC] and nucleic acid amplification testing [NAAT]) are confounde

174 The primary outcome was microbial cure by nucleic acid amplification testing at day 28.

175 sting was performed, including serologic and nucleic acid amplification testing for B. burgdorferi an

176 imens, a useful characteristic in the age of nucleic acid amplification testing for gonococcal infect

177 For all urine specimens, UA, culture, and nucleic acid amplification testing for Neisseria gonorrh

178 North Carolina has added nucleic acid amplification testing for the human immunod

179 f C. trachomatis- or N. gonorrhoeae-specific nucleic acid amplification testing in this metropolitan

180 the introduction of diagnostic M. genitalium nucleic acid amplification testing including antimicrobi

181 Nucleic acid amplification testing is a very powerful me

182 and the necessary specialized growth media, nucleic acid amplification testing is currently the most

183 These data support the use of targeted nucleic acid amplification testing of individual donatio

184 elps improves detection of SARS-CoV-2 RNA by nucleic acid amplification testing of potential patients

185 years, beginning in 2014, by means of rapid nucleic acid amplification testing of spontaneously expe

186 Screening of broth enrichment fluids by nucleic acid amplification testing requires careful hand

187 dictive value of the algorithm that included nucleic acid amplification testing were greater than 0.9

188 Although nucleic acid amplification testing would detect N. gonor

189 specimens, known to be gonorrhea positive by nucleic acid amplification testing, provided by females

190 treatment failure determined on the basis of nucleic acid amplification testing, sexual history, and

191 erpretation of gonorrhea tests of cure using nucleic acid amplification testing, this study examined

192 acutely viremic blood donors, identified by nucleic acid amplification testing, were enrolled and mo

193 other month were tested for M. genitalium by nucleic acid amplification testing.

194 in whom WNV infection was identified by WNV nucleic acid amplification testing.

195 ts and laboratory-based specimen pooling for nucleic acid amplification testing.

196 ymptomatic sexual health screening underwent nucleic acid amplification testing; positive samples and

197 Digital nucleic acid amplification tests (digital NAATs) have em

198 We describe the adoption of nucleic acid amplification tests (NAAT) for Clostridium

199 uction of rapid serologic tests (RT) and HIV nucleic acid amplification tests (NAAT).

200 ected daily rectal and vaginal specimens for nucleic acid amplification tests (NAATs) and completed w

201 Commercial nucleic acid amplification tests (NAATs) are becoming av

202 Nucleic acid amplification tests (NAATs) are common in l

203 Nucleic acid amplification tests (NAATs) are expensive.

204 lty of culture of this fastidious bacterium, nucleic acid amplification tests (NAATs) are necessary f

205 Nucleic acid amplification tests (NAATs) are quickly bec

206 Nucleic acid amplification tests (NAATs) are reliable to

207 Nucleic acid amplification tests (NAATs) are the primary

208 dels to adjust for the higher sensitivity of nucleic acid amplification tests (NAATs) as compared wit

209 ning from toxin enzyme immunoassays (EIA) to nucleic acid amplification tests (NAATs) as the primary

210 Because nucleic acid amplification tests (NAATs) do not distingu

211 suggested approaches for confirming positive nucleic acid amplification tests (NAATs) for Chlamydia t

212 cent sexual assault survivors include use of nucleic acid amplification tests (NAATs) for detection o

213 is study was to determine the added value of nucleic acid amplification tests (NAATs) for detection o

214 gnostic transcription-mediated amplification nucleic acid amplification tests (NAATs) for diagnosis o

215 Nucleic acid amplification tests (NAATs) for enterovirus

216 rapid development of commercially available nucleic acid amplification tests (NAATs) for influenza v

217 r, the true limitation in the realization of nucleic acid amplification tests (NAATs) for near-patien

218 udy evaluated the performance of culture and nucleic acid amplification tests (NAATs) for rectal chla

219 Determining whether and when multiplex nucleic acid amplification tests (NAATs) for respiratory

220 Currently, there are no FDA-approved nucleic acid amplification tests (NAATs) for the detecti

221 was to define the performance of culture and nucleic acid amplification tests (NAATs) for the diagnos

222 The use of nucleic acid amplification tests (NAATs) for the diagnos

223 The use of some nucleic acid amplification tests (NAATs) for the diagnos

224 The currently available nucleic acid amplification tests (NAATs) for trichomonia

225 The development and maturation of automated nucleic acid amplification tests (NAATs) has greatly imp

226 self-obtained vaginal specimens processed by nucleic acid amplification tests (NAATs) has significant

227 ple, recent studies with ribosomal RNA-based nucleic acid amplification tests (NAATs) have demonstrat

228 Nucleic acid amplification tests (NAATs) have frequently

229 Nucleic acid amplification tests (NAATs) have revolution

230 DTs), digital immunoassays (DIAs), and rapid nucleic acid amplification tests (NAATs) in children and

231 Over the last decade, nucleic acid amplification tests (NAATs) including polym

232 o-molecular AST", a strategy that transforms nucleic acid amplification tests (NAATs) into phenotypic

233 d have worse outcomes than those detected by nucleic acid amplification tests (NAATs) only.

234 Nucleic acid amplification tests (NAATs) such as real-ti

235 a CT (ACT) (Hologic Inc., San Diego, CA) are nucleic acid amplification tests (NAATs) that detect Chl

236 . Food and Drug Administration (FDA)-cleared nucleic acid amplification tests (NAATs) to culture usin

237 The use of nucleic acid amplification tests (NAATs) to diagnose Nei

238 The specificity of nucleic acid amplification tests (NAATs) used for early

239 ribing the diagnostic performance of malaria nucleic acid amplification tests (NAATs) using these spe

240 , and illumigene group B Streptococcus (GBS) nucleic acid amplification tests (NAATs) were compared t

241 At that time, nucleic acid amplification tests (NAATs) were just becom

242 Several Neisseria gonorrhoeae nucleic acid amplification tests (NAATs) with high sensi

243 compared the clinical sensitivities of three nucleic acid amplification tests (NAATs), the Hologic Pa

244 compare the performance of two FDA-approved nucleic acid amplification tests (NAATs), the Panther Fu

245 The use of nonculture methods, such as nucleic acid amplification tests (NAATs), to evaluate pr

246 tinct MAMEF assays were compared to those of nucleic acid amplification tests (NAATs).

247 rus (DENV) detection, including a variety of nucleic acid amplification tests (NAATs).

248 FA) testing, immunohistochemistry (IHC), and nucleic acid amplification tests (NAATs).

249 Nucleic acid amplification tests (NAATs)integrated on a

250 ulture-based systems, simplified versions of nucleic acid amplification tests (such as the Xpert MTB/

251 es and gaining in use are techniques such as nucleic acid amplification tests and mass spectroscopy t

252 rformance of HOLMES is comparable to that of nucleic acid amplification tests and near million-fold i

253 Nucleic acid amplification tests and point-of-care tests

254 genitalium coinfections were evaluated using nucleic acid amplification tests and were negative at 1

255 Nucleic acid amplification tests are accurate for diagno

256 proaches to diagnosis remain inaccurate, and nucleic acid amplification tests are also compromised by

257 Nucleic acid amplification tests are commonly used to di

258 Nucleic acid amplification tests are increasingly used t

259 In 10 new studies of asymptomatic patients, nucleic acid amplification tests demonstrated sensitivit

260 Nucleic acid amplification tests detected CT, MG, and TV

261 gonorrhoeae and Chlamydia trachomatis using nucleic acid amplification tests detects greater numbers

262 ly impact the performance characteristics of nucleic acid amplification tests for B. pertussis.

263 Nucleic acid amplification tests for C trachomatis, N go

264 We evaluated the performance of two nucleic acid amplification tests for detecting Chlamydia

265 We compared two rapid, point-of care nucleic acid amplification tests for detection of influe

266 Since implementation of nucleic acid amplification tests for N. gonorrhoeae iden

267 ree commercial identification kits and three nucleic acid amplification tests for the identification

268 Nucleic acid amplification tests for Trichomonas vaginal

269 Nucleic acid amplification tests have become a common me

270 Highly sensitive and specific nucleic acid amplification tests have become the diagnos

271 Nucleic acid amplification tests have been widely used i

272 While nucleic acid amplification tests have great potential as

273 Nucleic acid amplification tests identify BI/NAP1/027 ra

274 The use of nucleic acid amplification tests of "minipools" of 16 sa

275 ions and the incremental yield and safety of nucleic acid amplification tests of individual donations

276 retrospectively using enzyme immunoassay and nucleic acid amplification tests on stored specimens.

277 nd discrepancies were resolved by additional nucleic acid amplification tests or sequencing.

278 In many clinical microbiology laboratories, nucleic acid amplification tests such as PCR have become

279 Nucleic acid amplification tests such as PCR have signif

280 y have residual DNA in sputum that confounds nucleic acid amplification tests such as Xpert MTB/RIF.

281 Food and Drug Administration-approved nucleic acid amplification tests to determine the sensit

282 amydia trachomatis and Neisseria gonorrhoea (nucleic acid amplification tests).

283 rovide valid specimens for HPV testing using nucleic acid amplification tests, although a few cytolog

284 imens from women are suitable substrates for nucleic acid amplification tests, but enzyme immunoassay

285 strategies, newer testing methods, including nucleic acid amplification tests, have enhanced sensitiv

286 Emerging POC microbiology tests, especially nucleic acid amplification tests, have the potential to

287 n will expand the diagnostic applications of nucleic acid amplification tests, in particular for near

288 ddition of toxin enzyme immunoassay (EIA) to nucleic acid amplification tests, including PCR, creates

289 Nucleic acid amplification tests, such as PCR, are the m

290 With a reference standard of two different nucleic acid amplification tests, the sensitivity and sp

291 reatly expand the diagnostic applications of nucleic acid amplification tests.

292 (UU-2), and Trichomonas vaginalis (TV) using nucleic acid amplification tests.

293 ons related to the optimal use of SARS-CoV-2 nucleic acid amplification tests.

294 sts, direct fluorescent antibody assays, and nucleic acid amplification tests.

295 f Gram-stained samples, bacterial culture or nucleic acid amplification tests.

296 horolysis-activated polymerization [PAP]) of nucleic acid amplification that uses 3' blocked primers

297 e quantitative electrochemical monitoring of nucleic acid amplification through PCR is a promising re

298 Electrical detection of nucleic acid amplification through pH changes associated

299 Real-time nucleic acid amplification, whereby the amplification ra

300 of rolling circle amplification (RCA)-based nucleic acid amplification with an on-chip size-selectiv